Literature DB >> 35465068

Nonalcoholic Fatty Liver Disease in Children.

Katherine F Sweeny1, Christine K Lee1,2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It represents a spectrum of disease from simple hepatic steatosis to steatohepatitis that may develop into progressive hepatic fibrosis and even cirrhosis. NAFLD is the most rapidly increasing indication for liver transplantation in adults. In children, the incidence of NAFLD has also increased over the past decade. Although the majority of children with NAFLD are overweight or obese, there is an increasing subset of children with normal body mass index with so-called lean NAFLD. NAFLD in children is associated with several extrahepatic manifestations, including hyperlipidemia, insulin resistance, and obstructive sleep apnea. The pathogenesis of NAFLD in children involves a multifactorial interaction among genetics, in utero exposures, early childhood exposures, and ongoing nutritional exposures. Although there are some similarities between pediatric NAFLD and adult NAFLD, liver biopsies in children show histologic differences between the two. The current standard-of-care treatment of NAFLD in children is lifestyle change to decrease caloric intake and increase physical activity. There are no medications currently approved for the treatment of NAFLD in children. This article aims to summarize the current understanding of pediatric NAFLD and future directions for intervention and therapeutic aims.
Copyright © 2021, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Nonalcoholic fatty liver disease; children; chronic liver disease; nonalcoholic steatohepatitis; obesity

Year:  2021        PMID: 35465068      PMCID: PMC9021174     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  98 in total

1.  Epidemiology of chronic liver diseases in the USA in the past three decades.

Authors:  Zobair M Younossi; Maria Stepanova; Youssef Younossi; Pegah Golabi; Alita Mishra; Nila Rafiq; Linda Henry
Journal:  Gut       Date:  2019-07-31       Impact factor: 23.059

2.  Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.

Authors:  Christina N Katsagoni; George V Papatheodoridis; Panagiota Ioannidou; Melanie Deutsch; Alexandra Alexopoulou; Nikolaos Papadopoulos; Maria-Vasiliki Papageorgiou; Elizabeth Fragopoulou; Meropi D Kontogianni
Journal:  Br J Nutr       Date:  2018-07       Impact factor: 3.718

3.  Validation of Transient Elastography Cut Points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children's Hospital Experience.

Authors:  Christine K Lee; Paul D Mitchell; Roshan Raza; Sarah Harney; Shanna M Wiggins; Maureen M Jonas
Journal:  J Pediatr       Date:  2018-07       Impact factor: 4.406

4.  Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Lisa M Glass; Rolland C Dickson; Joseph C Anderson; Arief A Suriawinata; Juan Putra; Brian S Berk; Arifa Toor
Journal:  Dig Dis Sci       Date:  2014-10-30       Impact factor: 3.199

5.  The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.

Authors:  A E Feldstein; P Charatcharoenwitthaya; S Treeprasertsuk; J T Benson; F B Enders; P Angulo
Journal:  Gut       Date:  2009-07-21       Impact factor: 23.059

Review 6.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

Review 7.  Nutrition and Genetics in NAFLD: The Perfect Binomium.

Authors:  Marica Meroni; Miriam Longo; Alice Rustichelli; Paola Dongiovanni
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

8.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

9.  A Low ω-6 to ω-3 PUFA Ratio (n-6:n-3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth.

Authors:  Michelle A Van Name; Mary Savoye; Jennifer M Chick; Brittany T Galuppo; Ariel E Feldstein; Bridget Pierpont; Casey Johnson; Veronika Shabanova; Udeme Ekong; Pamela L Valentino; Grace Kim; Sonia Caprio; Nicola Santoro
Journal:  J Nutr       Date:  2020-09-01       Impact factor: 4.798

10.  The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD.

Authors:  Taylor K Soderborg; Sarah E Clark; Christopher E Mulligan; Rachel C Janssen; Lyndsey Babcock; Diana Ir; Bridget Young; Nancy Krebs; Dominick J Lemas; Linda K Johnson; Tiffany Weir; Laurel L Lenz; Daniel N Frank; Teri L Hernandez; Kristine A Kuhn; Angelo D'Alessandro; Linda A Barbour; Karim C El Kasmi; Jacob E Friedman
Journal:  Nat Commun       Date:  2018-10-26       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.